Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RYAN J MALONE

Allopathic & Osteopathic Physicians Urology

NPI
1417913088
CMS profile
659922
Location
JEFFERSONVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$24,933.26

273 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 273 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RYAN J MALONE

NPI 1417913088 · CMS profile ID 659922

Allopathic & Osteopathic Physicians / Urology

JEFFERSONVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 273 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417913088?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RYAN J MALONE, NPI 1417913088, CMS profile ID 659922. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 273 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417913088?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RYAN J MALONE, NPI 1417913088, CMS profile ID 659922. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 273 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417913088?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RYAN J MALONE, NPI 1417913088, CMS profile ID 659922, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 273 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1417913088?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

273 matching records · $24,933.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 273 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 273.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sumitomo Pharma America, Inc. $19.4609/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148885590 CMS
ACCORD HEALTHCARE, INC. $9.0009/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120081750 CMS
Merck Sharp & Dohme LLC $21.6709/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141771148 CMS
Dendreon Pharmaceuticals LLC $8.7509/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149319730 CMS
Novartis Pharmaceuticals Corporation $20.3408/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087056086 CMS
PFIZER INC. $6.2808/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131988575 CMS
Myriad Genetic Laboratories, Inc. $14.3708/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152535625 CMS
Myriad Genetic Laboratories, Inc. $123.6708/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152535627 CMS
Sumitomo Pharma America, Inc. $22.4208/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148885588 CMS
Tolmar, Inc. $20.1608/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138708261 CMS
Novartis Pharmaceuticals Corporation $22.8508/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087056088 CMS
ACCORD HEALTHCARE, INC. $6.6708/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120081574 CMS
Dendreon Pharmaceuticals LLC $8.9308/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149319728 CMS
Janssen Biotech, Inc. $19.3708/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078624958 CMS
Dendreon Pharmaceuticals LLC $24.0208/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149319726 CMS
Verity Pharmaceuticals Inc. $13.8108/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080608497 CMS
Tempus AI, Inc $29.4708/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150169182 CMS
AstraZeneca Pharmaceuticals LP $25.3608/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104646965 CMS
ACCORD HEALTHCARE, INC. $7.3608/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120081406 CMS
Janssen Biotech, Inc. $13.3208/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078624992 CMS
Sumitomo Pharma America, Inc. $22.6408/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148885586 CMS
Janssen Biotech, Inc. $131.0408/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078624854 CMS
Dendreon Pharmaceuticals LLC $9.5708/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149319724 CMS
Janssen Scientific Affairs, LLC $817.5008/13/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078850446 CMS
ABBVIE INC. $18.5708/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104948299 CMS
PFIZER INC. $18.9808/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131902363 CMS
Bayer Healthcare Pharmaceuticals Inc. $2.2308/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086087127 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.6008/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086237982 CMS
Novartis Pharmaceuticals Corporation $26.4508/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087056084 CMS
Medtronic, Inc. $108.0408/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119310432 CMS
Astellas Pharma US Inc $18.1407/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139393736 CMS
Sumitomo Pharma America, Inc. $14.8807/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148885584 CMS
ACCORD HEALTHCARE, INC. $5.6407/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120080988 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.1007/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086165160 CMS
Janssen Biotech, Inc. $19.3107/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078624921 CMS
Merck Sharp & Dohme LLC $25.0207/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141771146 CMS
Janssen Biotech, Inc. $27.4107/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078625056 CMS
PFIZER INC. $20.2807/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131813010 CMS
Dendreon Pharmaceuticals LLC $13.6107/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149319722 CMS
Janssen Biotech, Inc. $7.8707/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078624890 CMS
ACCORD HEALTHCARE, INC. $17.2107/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120080560 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.6106/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086231448 CMS
Janssen Biotech, Inc. $14.9606/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078625043 CMS
Astellas Pharma US Inc $20.7706/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139371561 CMS
Janssen Scientific Affairs, LLC $126.5006/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078850422 CMS
ACCORD HEALTHCARE, INC. $24.7106/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120080148 CMS
Janssen Biotech, Inc. $111.1606/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078624649 CMS
PFIZER INC. $19.4306/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131700903 CMS
Janssen Biotech, Inc. $119.7006/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078625036 CMS
ACCORD HEALTHCARE, INC. $11.6706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120080042 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,246.19 42
PY2020 $983.64 47
PY2021 $1,712.04 51
PY2022 $3,469.48 106
PY2023 $23,211.40 253
PY2024 $24,933.26 273
PY2025 $40,978.12 280

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $17,375.00 4
PY2025 Principal investigator $2,658,908.34 244
PY2024 Principal investigator $3,625,939.10 224
PY2023 Principal investigator $734,799.63 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

248 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $5,152.00 12/29/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175355810
Principal investigator 1 Janssen Research & Development, LLC $95,192.54 12/29/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175356072
Principal investigator 1 PFIZER INC. $46,207.89 12/28/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726544
Principal investigator 1 Janssen Research & Development, LLC $3,925.00 12/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355725
Principal investigator 1 Janssen Research & Development, LLC $1,050.95 12/15/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175355948
Principal investigator 1 Janssen Research & Development, LLC $7,457.55 12/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175355893
Principal investigator 1 MEDIVATION LLC. $243.75 12/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739086
Principal investigator 1 MEDIVATION LLC. $243.75 12/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740394
Principal investigator 1 MEDIVATION LLC. $243.75 12/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228747215
Principal investigator 1 Janssen Research & Development, LLC $11,775.00 12/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355703
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 12/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356221
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 12/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356320
Principal investigator 1 PFIZER INC. $46,207.89 12/01/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727307
Principal investigator 1 PFIZER INC. $46,207.89 11/28/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727463
Principal investigator 1 Janssen Research & Development, LLC $5,888.40 11/24/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175356353
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 11/14/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409596
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 11/14/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409698
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 11/14/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409706
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 11/14/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409812
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,517.93 11/14/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409846
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,517.93 11/14/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409880
Principal investigator 1 Janssen Research & Development, LLC $240.00 11/14/2025 Non-covered Recipient Entity
First Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175217394
Principal investigator 1 Janssen Research & Development, LLC $5,152.00 11/07/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175355804
Principal investigator 1 Janssen Research & Development, LLC $7,850.00 11/07/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356117
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,500.00 11/06/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892527
Principal investigator 1 Dendreon Pharmaceuticals LLC $210.00 11/06/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892531
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,000.00 11/06/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892536
Principal investigator 1 MEDIVATION LLC. $1,267.50 11/04/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739797
Principal investigator 1 MEDIVATION LLC. $1,267.50 11/04/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228747212
Principal investigator 1 MEDIVATION LLC. $1,161.25 11/04/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228747753
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 11/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355693
Principal investigator 1 Janssen Research & Development, LLC $1,104.00 11/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355904
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 11/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355939
Principal investigator 1 Janssen Research & Development, LLC $300.00 11/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355962
Principal investigator 1 Janssen Research & Development, LLC $7,550.00 11/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355978
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 11/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356272
Principal investigator 1 Janssen Research & Development, LLC $55,063.34 11/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175356290
Principal investigator 1 Janssen Research & Development, LLC $2,555.95 10/30/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175355860
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $2,533.38 10/29/2025 Non-covered Recipient Entity
First Urology PSC
C3300-201 No dispute reported 06/30/2026 1227680583
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $335.88 10/29/2025 Non-covered Recipient Entity
First Urology PSC
C3300-201 No dispute reported 06/30/2026 1227681440
Principal investigator 1 Janssen Research & Development, LLC $1,104.00 10/29/2025 Non-covered Recipient Entity
First Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175217371
Principal investigator 1 Janssen Research & Development, LLC $6,950.00 10/17/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients No dispute reported 06/30/2026 1175355926
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 10/15/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409962
Principal investigator 1 Ferring Pharmaceuticals AS $44,312.40 10/14/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States No dispute reported 06/30/2026 1242061195
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,145.00 10/10/2025 Non-covered Recipient Entity
First Urology PSC
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225419717
Principal investigator 1 Janssen Research & Development, LLC $2,600.00 10/06/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175356251
Principal investigator 1 Janssen Research & Development, LLC $23,550.00 10/06/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356314
Principal investigator 1 Janssen Research & Development, LLC $1,153.00 10/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175355834
Principal investigator 1 Janssen Research & Development, LLC $58,043.34 10/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175356190
Principal investigator 1 MEDIVATION LLC. $1,161.25 10/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739623
Principal investigator 1 MEDIVATION LLC. $1,161.25 10/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740564
Principal investigator 1 PFIZER INC. $46,207.89 09/30/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727305
Principal investigator 1 Janssen Research & Development, LLC $2,555.95 09/29/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175356102
Principal investigator 1 PFIZER INC. $46,207.89 09/29/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727621
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 09/17/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410366
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 09/15/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355786
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 09/15/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355912
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 09/15/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356034
Principal investigator 1 PFIZER INC. $46,207.89 09/10/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726230
Principal investigator 1 PFIZER INC. $46,207.89 09/09/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727387
Principal investigator 1 Janssen Research & Development, LLC $88,166.94 09/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355933
Principal investigator 1 Janssen Research & Development, LLC $27,475.00 09/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356213
Principal investigator 1 MEDIVATION LLC. $1,161.25 09/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228743303
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 08/28/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409298
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,412.54 08/28/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409330
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 08/28/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409386
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,517.93 08/28/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409430
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,412.54 08/28/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409448
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 08/28/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409464
Principal investigator 1 Janssen Research & Development, LLC $1,050.95 08/28/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175355920
Principal investigator 1 Janssen Research & Development, LLC $960.00 08/18/2025 Non-covered Recipient Entity
First Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175217377
Principal investigator 1 Janssen Research & Development, LLC $12,690.00 08/11/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175356378
Principal investigator 1 Dendreon Pharmaceuticals LLC $750.00 08/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892278
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 08/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892282
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 08/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892286
Principal investigator 1 Dendreon Pharmaceuticals LLC $750.00 08/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892290
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 08/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892294
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 08/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892298
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 08/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892301
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 08/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892305
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 08/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892308
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 08/08/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247892313
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $660.00 08/07/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409256
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $660.00 08/07/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409302
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $660.00 08/07/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409370
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $660.00 08/07/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409404
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $660.00 08/07/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409412
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $660.00 08/07/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409438
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,750.00 08/07/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409462
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $660.00 08/07/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409482
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $660.00 08/07/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409508
Principal investigator 1 Janssen Research & Development, LLC $1,050.95 07/28/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175355671
Principal investigator 1 Janssen Research & Development, LLC $60,372.96 07/28/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175356133
Principal investigator 1 Janssen Research & Development, LLC $3,925.00 07/28/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356298
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 07/25/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355733
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 07/25/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356110
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,517.93 07/16/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409108
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 07/16/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409112
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 07/16/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409120
Principal investigator 1 Janssen Research & Development, LLC $7,850.00 07/07/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356242
Principal investigator 1 Janssen Research & Development, LLC $42,409.48 07/04/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175356088
Principal investigator 1 Janssen Research & Development, LLC $2,306.00 07/04/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175356336
Principal investigator 1 MEDIVATION LLC. $1,161.25 07/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723506
Principal investigator 1 MEDIVATION LLC. $1,161.25 07/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228742605
Principal investigator 1 MEDIVATION LLC. $1,161.25 07/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756360
Principal investigator 1 Janssen Research & Development, LLC $6,950.00 06/23/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175355771
Principal investigator 1 Janssen Research & Development, LLC $14,880.00 06/23/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175356282
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $512.50 06/12/2025 Non-covered Recipient Entity
First Urology PSC
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225402509
Principal investigator 1 Janssen Research & Development, LLC $23,850.00 06/09/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355852
Principal investigator 1 Janssen Research & Development, LLC $108,393.64 06/06/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175356056
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 06/04/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408070
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 06/04/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408112
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 06/04/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408236
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 06/04/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408302
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 06/04/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408330
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 06/04/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408396
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 06/04/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408412
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 06/04/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408426
Principal investigator 1 Janssen Research & Development, LLC $6,385.00 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m No dispute reported 06/30/2026 1175355658
Principal investigator 1 Janssen Research & Development, LLC $6,750.00 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355888
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355955
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356266
Principal investigator 1 MEDIVATION LLC. $243.75 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228722762
Principal investigator 1 MEDIVATION LLC. $243.75 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789859
Principal investigator 1 MEDIVATION LLC. $243.75 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790567
Principal investigator 1 MEDIVATION LLC. $1,161.25 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790625
Principal investigator 1 MEDIVATION LLC. $243.75 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791962
Principal investigator 1 MEDIVATION LLC. $243.75 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792364
Principal investigator 1 MEDIVATION LLC. $243.75 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792624
Principal investigator 1 MEDIVATION LLC. $243.75 06/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792948
Principal investigator 1 Janssen Research & Development, LLC $1,314.00 05/30/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175356368
Recipient Dendreon Pharmaceuticals LLC $485.00 05/29/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891370
Recipient Dendreon Pharmaceuticals LLC $4,560.00 05/29/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891373
Recipient Dendreon Pharmaceuticals LLC $4,210.00 05/29/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891377
Recipient Dendreon Pharmaceuticals LLC $8,120.00 05/29/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891381
Principal investigator 1 Dendreon Pharmaceuticals LLC $970.00 05/29/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
ProvONE No dispute reported 06/30/2026 1247891932
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,560.00 05/29/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
ProvONE No dispute reported 06/30/2026 1247891934
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,210.00 05/29/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
ProvONE No dispute reported 06/30/2026 1247891939
Principal investigator 1 Dendreon Pharmaceuticals LLC $8,120.00 05/29/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
ProvONE No dispute reported 06/30/2026 1247891942
Principal investigator 1 Janssen Research & Development, LLC $27,060.00 05/29/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355795
Principal investigator 1 Janssen Research & Development, LLC $6,385.00 05/12/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355710
Principal investigator 1 MEDIVATION LLC. $1,161.25 05/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789835
Principal investigator 1 MEDIVATION LLC. $1,161.25 05/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790446
Principal investigator 1 MEDIVATION LLC. $243.75 05/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790952
Principal investigator 1 MEDIVATION LLC. $1,161.25 05/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792316
Principal investigator 1 MEDIVATION LLC. $1,161.25 05/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792372
Principal investigator 1 MEDIVATION LLC. $1,161.25 05/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792581
Principal investigator 1 MEDIVATION LLC. $1,161.25 05/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792637
Principal investigator 1 MEDIVATION LLC. $1,161.25 05/05/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793773
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $36.40 05/01/2025 Non-covered Recipient Entity
First Urology PSC
C3300-201 No dispute reported 06/30/2026 1227680279
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,024.40 05/01/2025 Non-covered Recipient Entity
First Urology PSC
C3300-201 No dispute reported 06/30/2026 1227682552
Principal investigator 1 Janssen Research & Development, LLC $1,050.95 05/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175356151
Principal investigator 1 Janssen Research & Development, LLC $3,925.00 04/28/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355816
Principal investigator 1 Janssen Research & Development, LLC $79,470.72 04/28/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175356063
Principal investigator 1 Janssen Research & Development, LLC $4,120.00 04/25/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355685
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 04/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405310
Principal investigator 1 Janssen Research & Development, LLC $6,950.00 04/11/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175355778
Principal investigator 1 Janssen Research & Development, LLC $6,950.00 04/11/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175355877
Principal investigator 1 Janssen Research & Development, LLC $6,950.00 04/11/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175356174
Principal investigator 1 Janssen Research & Development, LLC $14,100.00 04/10/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356181
Principal investigator 1 Janssen Research & Development, LLC $2,306.00 04/07/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355823
Principal investigator 1 Janssen Research & Development, LLC $81,283.38 04/07/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175356159
Principal investigator 1 Janssen Research & Development, LLC $14,100.00 04/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355664
Principal investigator 1 Janssen Research & Development, LLC $14,650.00 04/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356231
Principal investigator 1 MEDIVATION LLC. $243.75 04/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789821
Principal investigator 1 MEDIVATION LLC. $243.75 04/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789839
Principal investigator 1 MEDIVATION LLC. $243.75 04/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791800
Principal investigator 1 MEDIVATION LLC. $243.75 04/01/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791979
Principal investigator 1 Janssen Research & Development, LLC $12,000.00 03/31/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355986
Principal investigator 1 Janssen Research & Development, LLC $1,050.95 03/31/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175356329
Principal investigator 1 Dendreon Pharmaceuticals LLC $15,000.00 03/28/2025 Non-covered Recipient Entity
ASSOCIATED UROLOGISTS OF NORTH CAROLINA
PROVONE STUDY No dispute reported 06/30/2026 1247891840
Principal investigator 1 Janssen Research & Development, LLC $6,213.40 03/27/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355971
Principal investigator 1 Janssen Research & Development, LLC $89,632.16 03/25/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355763
Principal investigator 1 Janssen Research & Development, LLC $2,460.00 03/25/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355844
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,517.93 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403179
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404179
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404646
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404760
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405078
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405080
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405196
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405400
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405440
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405442
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405588
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406032
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,051.21 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406578
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,412.54 03/24/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406580
Principal investigator 1 PFIZER INC. $46,206.12 03/24/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723594
Principal investigator 1 PFIZER INC. $46,206.12 03/23/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751961
Principal investigator 1 PFIZER INC. $46,207.89 03/23/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755604
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 03/21/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355992
Principal investigator 1 Janssen Research & Development, LLC $14,550.00 03/20/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356259
Principal investigator 1 Janssen Research & Development, LLC $300.00 03/14/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355649
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 03/14/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356204
Principal investigator 1 Janssen Research & Development, LLC $107.00 03/13/2025 Non-covered Recipient Entity
First Uro
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175217402
Principal investigator 1 Janssen Research & Development, LLC $6,385.00 03/10/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175356125
Principal investigator 1 Janssen Research & Development, LLC $11,025.00 03/07/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356041
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355677
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355756
Principal investigator 1 Janssen Research & Development, LLC $7,050.00 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356166
Principal investigator 1 Janssen Research & Development, LLC $1,050.95 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175356344
Principal investigator 1 MEDIVATION LLC. $243.75 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774378
Principal investigator 1 MEDIVATION LLC. $243.75 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774411
Principal investigator 1 MEDIVATION LLC. $243.75 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774419
Principal investigator 1 MEDIVATION LLC. $243.75 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775295
Principal investigator 1 MEDIVATION LLC. $243.75 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775923
Principal investigator 1 MEDIVATION LLC. $1,161.25 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776190
Principal investigator 1 MEDIVATION LLC. $243.75 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776210
Principal investigator 1 MEDIVATION LLC. $243.75 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778109
Principal investigator 1 MEDIVATION LLC. $243.75 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778393
Principal investigator 1 MEDIVATION LLC. $243.75 03/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228784781
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 02/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247891714
Principal investigator 1 Dendreon Pharmaceuticals LLC $8,120.00 02/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247891718
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 02/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247891741
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 02/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247891778
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 02/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247891798
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 02/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247891801
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 02/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247891805
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 02/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247891809
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 02/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247891814
Principal investigator 1 Dendreon Pharmaceuticals LLC $4,060.00 02/26/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
PROVONE STUDY No dispute reported 06/30/2026 1247891817
Principal investigator 1 Janssen Research & Development, LLC $7,400.00 02/21/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175355747
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 02/13/2025 Non-covered Recipient Entity
First Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175217386
Principal investigator 1 Janssen Research & Development, LLC $123,601.12 02/10/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355868
Principal investigator 1 Janssen Research & Development, LLC $54,650.00 02/10/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175356027
Principal investigator 1 Janssen Research & Development, LLC $8,771.00 02/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355717
Principal investigator 1 Janssen Research & Development, LLC $2,101.90 02/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo No dispute reported 06/30/2026 1175356360
Principal investigator 1 MEDIVATION LLC. $3,375.00 02/03/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776387
Principal investigator 1 PFIZER INC. $46,206.12 02/03/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752639
Principal investigator 1 PFIZER INC. $46,206.12 02/01/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754030
Principal investigator 1 PFIZER INC. $46,207.89 02/01/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755607
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $512.50 01/30/2025 Non-covered Recipient Entity
First Urology PSC
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225406036
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 01/27/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403137
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,051.24 01/27/2025 Non-covered Recipient Entity
Mihai Gheorghiade Northwestern University Feinberg School Of Medicine
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405308
Principal investigator 1 MEDIVATION LLC. $1,161.25 01/27/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774479
Principal investigator 1 MEDIVATION LLC. $1,161.25 01/27/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775025
Principal investigator 1 Janssen Research & Development, LLC $460.00 01/23/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175356094
Principal investigator 1 PFIZER INC. $46,206.12 01/23/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752693
Principal investigator 1 PFIZER INC. $46,206.12 01/22/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752361
Principal investigator 1 PFIZER INC. $46,207.89 01/22/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228758950
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 01/14/2025 Non-covered Recipient Entity
First Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175217364
Principal investigator 1 Janssen Research & Development, LLC $1,507.95 01/14/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175356306
Principal investigator 1 Janssen Research & Development, LLC $125,394.68 01/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355740
Principal investigator 1 MEDIVATION LLC. $1,161.25 01/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777914
Principal investigator 1 MEDIVATION LLC. $1,161.25 01/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228785571
Principal investigator 1 MEDIVATION LLC. $3,375.00 01/02/2025 Non-covered Recipient Entity
FIRST UROLOGY PSC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786772
Principal investigator 1 PFIZER INC. $46,206.12 01/02/2025 Non-covered Recipient Entity
First Urology Research
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751330